{"id":293381,"date":"2025-04-01T00:00:00","date_gmt":"2025-04-01T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnemd0010-2024-biopharma-primary-biliary-cholangitis-unmet-need-unmet-need-primary-biliary\/"},"modified":"2026-03-31T10:26:38","modified_gmt":"2026-03-31T10:26:38","slug":"unnemd0010-2025-biopharma-primary-biliary-cholangitis-unmet-need-unmet-need-primary-biliary-cholangitis-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnemd0010-2025-biopharma-primary-biliary-cholangitis-unmet-need-unmet-need-primary-biliary-cholangitis-us-eu\/","title":{"rendered":"Primary Biliary Cholangitis &#8211; Unmet Need &#8211; Unmet Need &#8211; Primary Biliary Cholangitis (US\/EU)"},"content":{"rendered":"<p>Primary biliary cholangitis (<abbr data-abbreviation-entity=\"5885\" title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr>) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and destruction of the interlobular bile ducts, followed by cholestasis, which drives debilitating fatigue and itch. <abbr data-abbreviation-entity=\"5885\" title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> culminates in liver fibrosis, cirrhosis, end-stage organ disease, and death. <abbr data-abbreviation-entity=\"5885\" title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> has no cure; the goal of treatment is to halt or slow the progression of liver disease, reduce the need for liver transplantation, and lower the risk of mortality. Ursodeoxycholic acid (<abbr data-abbreviation-entity=\"7499\" title=\"ursodeoxycholic acid\">UDCA<\/abbr>) is the mainstay of treatment, and Intercept\u2019s Ocaliva (obeticholic acid) is an option for patients who respond inadequately or are intolerant to <abbr data-abbreviation-entity=\"7499\" title=\"ursodeoxycholic acid\">UDCA<\/abbr>, despite the risk of serious liver injury. Recently, <abbr data-abbreviation-entity=\"5048\" title=\"peroxisome proliferator-activated receptor\">PPAR<\/abbr> agonists (Ipsen\u2019s Iqirvo [elafibranor] and Livdelzi [Gilead\u2019s seladelpar]) were approved for <abbr data-abbreviation-entity=\"5885\" title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr>. Although some of these drugs slow disease progression, addressing the underlying cause or showing meaningful improvement of symptoms remains a challenge. This analysis provides quantitative insights into key treatment drivers and gaps and opportunities in current unmet needs treatment, based on the insights of surveyed gastroenterologist and hepatologists.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the key treatment drivers and goals in <abbr data-abbreviation-entity=\"5885\" title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> treatment? How well do current therapies perform on these goals?<\/li>\n<li>What drug attributes are key influencers, and which of these have limited impact and which are hidden opportunities?<\/li>\n<li>Which unmet needs do physicians consider most crucial in the treatment of <abbr data-abbreviation-entity=\"5885\" title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and prices are acceptable to physicians for a hypothetical <abbr data-abbreviation-entity=\"5885\" title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> drug?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30 European gastroenterologists \/ hepatologists fielded in February 2025<\/p>\n<p><strong>Key drugs: <\/strong>Ursodeoxycholic acid, obeticholic acid, elafibranor, seladelpar, fibrates, oral corticosteroids, oral immunosuppressants<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Key feature<\/strong><\/p>\n<p>Target Product Profile (<abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-293381","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-primary-biliary-cholangitis","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293381\/revisions"}],"predecessor-version":[{"id":425379,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293381\/revisions\/425379"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=293381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}